Whilst CNS disorders are currently largely diagnosed based on their clinical presentation, they show heterogeneous clinical courses and response to the treatment. Here molecular imaging has begun to provide evidence of different molecular pathologies within

the same syndrome, potentially explaining some of the heterogeneity in CNS disorders. Inhibitors,research,lifescience,medical This has clear translational potential in schizophrenia where the finding that there are “dopaminergic” and “nondopaminergic” subtypes suggests the latter group could be identified for emerging alternatives to the dopamine blocking drugs that are currently available. The use of DaTscan for differentiation of parkinsonian syndromes has already made it to the clinic. Furthermore, as shown in schizophrenia and dementia, molecular imaging is beginning to be applied to identify high-risk groups prior to the onset of the frank disorder. There is thus the potential to intervene early, before disability has progressed, to prevent the onset of disorder. How molecular imaging can be applied for the development Inhibitors,research,lifescience,medical of new Icotinib ic50 treatments Molecular imaging has the potential to inform drug discovery in a number of ways. Firstly, it enables Inhibitors,research,lifescience,medical specific drug targets to be identified during the development and progression of a disorder. In schizophrenia, for example, molecular imaging has determined that current drug treatments act downstream of the major dopaminergic

abnormality, and has identified the presynaptic regulation of dopaminergic function as a key new target for drugs, whilst in AD the identification of neuroinflammation early in the disease has contributed to the development of anti-inflammatory Inhibitors,research,lifescience,medical treatments for the disease. Secondly, Inhibitors,research,lifescience,medical molecular imaging provides biomarkers to monitor treatments and provide pathophysiologically relevant end points to evaluate new therapies, as illustrated by the use of [18F]DOPA to monitor stem cell transplants in PD and [11C]PIB

to assess the efficacy of antiplaque agents in AD. Thirdly, it identifies endophenotypes to stratify patients Thalidomide with a given disorder on the basis of their underlying neurobiology. Such neurobiologcally defined endophenotypes will trigger significant paradigm shifts in new drug development for CNS disorders, from the past empirical approach based on trying treatments in heterogenous patient samples to targeting treatments to patients with a homogenous pathophysiology. Finally, the identification of molecular imaging biomarkers in a number of CNS disorders means it is possible to predict the efficacy of new treatments in animal models by measuring biomarkers, and to design clinical trials in an efficient way by subject stratification based on the endophenotypes. Acknowledgments Dr Kim thanks Sang Bin Hong for her kind assistance. Dr Kapur was supported by the NIHR BRC to SLaM NHS Trust.